Company profile: Leap Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted and immuno-oncology therapeutics in clinical development, including DKN-01 (monoclonal antibody against DKK1 for esophagogastric, gynecologic, colorectal, prostate, and lung cancers), FL-301 (monoclonal antibody against Claudin18.2 for gastric and pancreatic cancers), FL-302 (tetravalent bispecific targeting Claudin18.2 and CD137 to enhance T-cell activation), and FL-501 (designed to neutralize GDF15 to prevent cachexia and inhibit immunosuppressive tumor micro-environment in various cancers).
Products and services
- DKN-01: Humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for esophagogastric, gynecologic, colorectal, prostate, and lung cancers
- FL-302: Tetravalent bispecific antibody targeting Claudin18.2 and CD137, engineered to enhance T-cell activation and function in Claudin18.2+ tumor cells
- FL-301: Humanized monoclonal antibody targeting Claudin18.2, being developed for gastric and pancreatic cancers by Leap Therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Leap Therapeutics
Ancora Pharma
HQ: United States
Website
- Description: Provider of immune system modulation therapeutics using synthetic carbohydrates in the United States, offering vaccines against bacterial, parasitic, and viral infectious diseases, as well as therapeutics to treat cardiovascular and metabolic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ancora Pharma company profile →
Xilio Therapeutics
HQ: United States
Website
- Description: Provider of tumor-activated immuno-oncology therapies, including XTX101, an Fc-enhanced anti-CTLA-4 monoclonal antibody; XTX301, an engineered IL-12; XTX202, a tumor-selective protein-engineered IL-2; and XTX501, a tumor-activated PD1/IL2 bispecific, designed to enhance anti-tumor activity, reprogram the tumor microenvironment, improve tolerability, minimize peripheral toxicities, and overcome IL-2 receptor-mediated clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xilio Therapeutics company profile →
ImmuneXcite
HQ: United States
Website
- Description: Provider of a platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for disease targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuneXcite company profile →
Aimmune Therapeutics
HQ: United States
Website
- Description: Provider of characterized oral desensitization immunotherapy for food allergies, including PALFORZIA to reduce the frequency and severity of reactions to accidental peanut exposure. Develops investigational therapies for food, gastrointestinal, and metabolic-related diseases, conducts human clinical trials to support marketing applications to regulatory authorities, and offers an expanded access policy compliant with FDA regulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aimmune Therapeutics company profile →
Themis Bioscience
HQ: Austria
Website
- Description: Provider of vaccine R&D focused on preventing infectious diseases. The start-up biotechnology company concentrates on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Themis Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Leap Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Leap Therapeutics
2.2 - Growth funds investing in similar companies to Leap Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Leap Therapeutics
4.2 - Public trading comparable groups for Leap Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →